Theriva Biologics, Inc. (TOVX)

USD 1.17

(-0.29%)

EBITDA Summary of Theriva Biologics, Inc.

  • Theriva Biologics, Inc.'s latest annual EBITDA in 2023 was -19.85 Million USD , down -2.34% from previous year.
  • Theriva Biologics, Inc.'s latest quarterly EBITDA in 2024 Q2 was -4.38 Million USD , up 13.0% from previous quarter.
  • Theriva Biologics, Inc. reported an annual EBITDA of -21.58 Million USD in 2022, down -50.31% from previous year.
  • Theriva Biologics, Inc. reported an annual EBITDA of -14.18 Million USD in 2021, down -43.33% from previous year.
  • Theriva Biologics, Inc. reported a quarterly EBITDA of -5.35 Million USD for 2024 Q1, up 8.81% from previous quarter.
  • Theriva Biologics, Inc. reported a quarterly EBITDA of -5.83 Million USD for 2023 Q4, down -38.43% from previous quarter.

Annual EBITDA Chart of Theriva Biologics, Inc. (2023 - 1993)

Historical Annual EBITDA of Theriva Biologics, Inc. (2023 - 1993)

Year EBITDA EBITDA Growth
2023 -19.85 Million USD -2.34%
2022 -21.58 Million USD -50.31%
2021 -14.18 Million USD -43.33%
2020 -9.95 Million USD 35.43%
2019 -15.42 Million USD 27.87%
2018 -17.29 Million USD 41.81%
2017 -26 Million USD 27.25%
2016 -39.09 Million USD -36.15%
2015 -40.9 Million USD -75.01%
2014 -20.48 Million USD -72.56%
2013 -11.53 Million USD 28.66%
2012 -17.22 Million USD -328.84%
2011 -7.48 Million USD -227.8%
2010 -1.22 Million USD 62.39%
2009 -3.33 Million USD 52.9%
2008 -6.91 Million USD 30.43%
2007 -9.93 Million USD -144.71%
2006 -4.06 Million USD -217.43%
2005 -1.27 Million USD 0.0%
2002 -8.09 Million USD 17.04%
2001 -9.75 Million USD -52.05%
2000 -6.41 Million USD -166.74%
1999 -5.38 Million USD 18.69%
1998 -5.15 Million USD 183.51%
1997 -7.9 Million USD -31.08%
1996 -7.4 Million USD -1.37%
1995 -7.3 Million USD -14.06%
1994 -6.3 Million USD -82.86%
1993 -3.6 Million USD 0.0%

Peer EBITDA Comparison of Theriva Biologics, Inc.

Name EBITDA EBITDA Difference
AIM ImmunoTech Inc. -31.67 Million USD 37.326%
Ampio Pharmaceuticals, Inc. - USD Infinity%
Armata Pharmaceuticals, Inc. -39.91 Million USD 50.263%
Actinium Pharmaceuticals, Inc. -51.13 Million USD 61.17%
Azitra, Inc. -10.67 Million USD -86.017%
Can-Fite BioPharma Ltd. -8.18 Million USD -142.714%
Chromocell Therapeutics Corporation -6.86 Million USD -189.321%
Calidi Biotherapeutics, Inc. -28.6 Million USD 30.58%
CEL-SCI Corporation -27.56 Million USD 27.962%
iBio, Inc. -14.02 Million USD -41.602%
Lineage Cell Therapeutics, Inc. -24.73 Million USD 19.727%
MAIA Biotechnology, Inc. -20.18 Million USD 1.627%
Matinas BioPharma Holdings, Inc. -22.82 Million USD 13.016%
Navidea Biopharmaceuticals, Inc. -13.87 Million USD -43.091%
NovaBay Pharmaceuticals, Inc. -4.8 Million USD -313.625%
NanoViricides, Inc. -7.75 Million USD -155.946%
Oragenics, Inc. -20.87 Million USD 4.902%
BiomX Inc. -22.81 Million USD 12.978%
BiomX Inc. -22.81 Million USD 12.978%
Protalix BioTherapeutics, Inc. 11.65 Million USD 270.406%
Palatin Technologies, Inc. -29.03 Million USD 31.611%
Scorpius Holdings, Inc. -35.08 Million USD 43.408%